Compass Pathways
Generated by Meeveem AI
"Pioneering psilocybin therapy to transform care for treatment-resistant mental illness"
London
•51 - 250 Employees
•Clinical Systems
About Compass Pathways
Compass Pathways develops investigational psilocybin therapy for people living with serious mental health conditions who are not helped by current treatments. The company is advancing COMP360, a synthetic psilocybin formulation delivered with psychological support, through global phase 3 trials in treatment-resistant depression, with studies also underway in post-traumatic stress disorder and anorexia nervosa. The company works to the highest standards of scientific rigour, publishing all trial results and collaborating with leading research institutions and health systems. Compass is pioneering a treatment model that combines evidence-based innovation with compassionate care, ensuring therapies are accessible to all who might benefit.
Illustrative visual - may not reflect the actual offering.
Illustrative visual - may not reflect the actual offering.
227
Team Members
2016
Founded
Public
Funding
Hybrid
Work Environment
Our Vision
A world where everyone living with mental illness has access to evidence-based treatments that meaningfully reduce their suffering and restore hope for recovery, regardless of their background or where current therapies have failed.
Our Mission
At Compass Pathways, our mission is to accelerate patient access to evidence-based innovation in mental health.